IOVA (Iovance Biotherapeutics) LT-Debt-to-Total-Asset: 0.05 (As of Mar. 2026)

What is Iovance Biotherapeutics LT-Debt-to-Total-Asset?

Iovance Biotherapeutics IOVA +1.07% 44 LT-Debt-to-Total-Asset is 0.05 as of Mar. 2026. GuruFocus rates IOVA with a GF Score™ of 44/100 and a GF Value™ of $18.84 (Possible Value Trap). The stock has 2 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Iovance Biotherapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.05.

Iovance Biotherapeutics's long-term debt to total assets ratio increased from Mar. 2025 (0.05) to Mar. 2026 (0.05). It may suggest that Iovance Biotherapeutics is progressively becoming more dependent on debt to grow their business.

Iovance Biotherapeutics (NAS:IOVA) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Iovance Biotherapeutics LT-Debt-to-Total-Asset Related Terms

Iovance Biotherapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Iovance Biotherapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Iovance Biotherapeutics LT-Debt-to-Total-Asset Chart

Iovance Biotherapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.09

0.11

0.09

0.05

Iovance Biotherapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.05	0.05	0.05	0.05	0.05

44GF Score

Iovance Biotherapeutics Inc IOVA

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Iovance Biotherapeutics LT-Debt-to-Total-Asset Calculation

Iovance Biotherapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	44.401	/	913.17
	=	0.05

Iovance Biotherapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	43.877	/	925.665
	=	0.05

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.05 mean?

Iovance Biotherapeutics (IOVA) has a LT-Debt-to-Total-Asset of 0.05 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Iovance Biotherapeutics and its competitors.

Is Iovance Biotherapeutics' LT-Debt-to-Total-Asset too high?

Iovance Biotherapeutics' current LT-Debt-to-Total-Asset is 0.05. Overall, Iovance Biotherapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Iovance Biotherapeutics' LT-Debt-to-Total-Asset compare to HRMY and NRIX?

Iovance Biotherapeutics' LT-Debt-to-Total-Asset of 0.05 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Iovance Biotherapeutics and its competitors. Iovance Biotherapeutics's current LT-Debt-to-Total-Asset is 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Iovance Biotherapeutics stock overvalued right now?

Based on GuruFocus' analysis, Iovance Biotherapeutics (IOVA) is currently considered Possible Value Trap. The stock's GF Value™ is $18.84, compared to a current price of $4.23 — trading 77.5% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.05. Iovance Biotherapeutics' overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Iovance Biotherapeutics (IOVA), the current LT-Debt-to-Total-Asset is 0.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Iovance Biotherapeutics (IOVA) Overvalued in 2026?

Based on GuruFocus' analysis, Iovance Biotherapeutics stock appears to be undervalued. The current stock price of $4.23 is trading 77.5% below its estimated GF Value™ of $18.84. GuruFocus considers Iovance Biotherapeutics to be Possible Value Trap.

Key valuation signals for IOVA:

LT-Debt-to-Total-Asset: 0.05
GF Value™: $18.84 vs. price of $4.23 (77.5% below fair value)
GF Score™: 44/100 with 2 warning signs

No single metric tells the full story. See the IOVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Iovance Biotherapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies HRMY NRIX ZYME ADMA NVAX QURE ABCL SRPT RAPP RXRX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges 1IOVA:Italy 0JDK:UK 2LB:Germany 2LB:Germany

Address 825 Industrial Road, Suite 100, San Carlos, CA, USA, 94070

Website https://www.iovance.com

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

44GF Score

Get the complete analysis for IOVA

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.23

Price

$18.84

GF Value

View IOVA Analysis

See LT-Debt-to-Total-Asset data for all stocks →